Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-26
2010-12-07
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S492000, C548S493000
Reexamination Certificate
active
07846961
ABSTRACT:
α-crystalline form of the compound of formula (I):characterized by its powder X-ray diffraction diagram.Medicinal products containing the same which are useful as inhibitors of angiotensin I converting enzyme.
REFERENCES:
patent: 6696481 (2004-02-01), Damien et al.
patent: 0049658 (1982-04-01), None
patent: 01/87835 (2001-11-01), None
patent: 01/87836 (2001-11-01), None
patent: 0183439 (2001-11-01), None
patent: 03/087050 (2003-10-01), None
Byrn et al. Solid-State Chemistry of Drugs, 2d, Chapter 11 Hydrates and Solvates/hydrates, 233-247 (1999).
Morissette et al. Adv. Drug Delivery Rev. 2004, 56, 275-300.
Rouhi, Chem. & Eng. News, Feb. 24, 2003, 81(8), 32-35.
International Search Report for PCT/FR2007/000335 of Jun. 5, 2007.
Authouart Pascale
Coquerel Gerard
Lefebvre Loïc
Souvie Jean-Claude
Anderson Rebecca L
Barker Michael
Hueschen and Sage
Les Laboratoires Servier
LandOfFree
α crystalline form of the arginine salt of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with α crystalline form of the arginine salt of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and α crystalline form of the arginine salt of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4155804